KRAS ACTIVATING MUTATION
Clinical trials for KRAS ACTIVATING MUTATION explained in plain language.
Never miss a new study
Get alerted when new KRAS ACTIVATING MUTATION trials appear
Sign up with your email to follow new studies for KRAS ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets hard-to-treat lung cancer mutation
Disease control OngoingThis study tests whether combining two or three drugs can help people with a specific genetic subtype of non-small cell lung cancer (KRAS G12C). The drugs aim to block cancer growth signals. About 153 adults who have or haven't received prior KRAS-targeting therapy will take part…
Matched conditions: KRAS ACTIVATING MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cocktail of targeted drugs and chemo takes on pancreatic cancer
Disease control OngoingThis study tests whether adding two targeted drugs (avutometinib and defactinib) to standard chemotherapy can help people with metastatic pancreatic cancer that hasn't been treated yet. About 40 adults with this cancer will receive the combination. The goal is to find the safest …
Matched conditions: KRAS ACTIVATING MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:18 UTC